Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02641353 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate Bioavailability of Apremilast Oral Suspension Relative to Tablet and to Assess Effect of Food on the Pharmacokinetics (PK) of the Oral Suspension
A Phase 1 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT02641353 is a Phase 1 study that has completed, run by Amgen. The registered enrollment target is 34 participants.
The verdict
NCT02641353, a Phase 1 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
The purpose of this study is to assess how much of apremilast is found in the blood unchanged when administered as an oral suspension compared to when it is administered as a tablet formulation. The effect of food on apremilast oral suspension will also be evaluated. In addition, information on the safety and tolerability of apremilast will be obtained.
Interventions
- DRUG Apremilast Tablet
- DRUG Apremilast Oral Suspension
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2016-01-05 |
| Est. Completion | 2016-02-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02641353
The ClinicalTrials.gov registry entry for NCT02641353 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Apremilast Tablet is the first listed.
NCT02641353 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02641353 about?
NCT02641353 is a clinical study titled "Study to Evaluate Bioavailability of Apremilast Oral Suspension Relative to Tablet and to Assess Effect of Food on the Pharmacokinetics (PK) of the Oral Suspension". The purpose of this study is to assess how much of apremilast is found in the blood unchanged when administered as an oral suspension compared to when it is administered as a tablet formulation. The effect of food on apremilast oral suspension will also be evaluated. In addition, information on the ...
What is the current status of trial NCT02641353?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2016-01-05. Estimated completion is 2016-02-27.
What interventions are being tested in trial NCT02641353?
The interventions under investigation include: Apremilast Tablet (DRUG), Apremilast Oral Suspension (DRUG).
Who is sponsoring clinical trial NCT02641353?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.